- Home
- GOSS vs RDCM Comparison
GOSS vs RDCM Comparison
Compare GOSS & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- RDCM
- Stock Information
- Founded
- GOSS 2015
- RDCM 1985
- Country
- GOSS United States
- RDCM Israel
- Employees
- GOSS N/A
- RDCM N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- GOSS Health Care
- RDCM Technology
- Exchange
- GOSS Nasdaq
- RDCM Nasdaq
- Market Cap
- GOSS 203.3M
- RDCM 179.7M
- IPO Year
- GOSS 2019
- RDCM 1997
- Fundamental
- Price
- GOSS $1.12
- RDCM $12.72
- Analyst Decision
- GOSS Strong Buy
- RDCM Strong Buy
- Analyst Count
- GOSS 4
- RDCM 2
- Target Price
- GOSS $7.50
- RDCM $15.00
- AVG Volume (30 Days)
- GOSS 1.6M
- RDCM 30.7K
- Earning Date
- GOSS 05-13-2025
- RDCM 05-14-2025
- Dividend Yield
- GOSS N/A
- RDCM N/A
- EPS Growth
- GOSS N/A
- RDCM 79.17
- EPS
- GOSS N/A
- RDCM 0.43
- Revenue
- GOSS $114,701,000.00
- RDCM $61,009,000.00
- Revenue This Year
- GOSS N/A
- RDCM $14.93
- Revenue Next Year
- GOSS $172.31
- RDCM $10.74
- P/E Ratio
- GOSS N/A
- RDCM $28.02
- Revenue Growth
- GOSS N/A
- RDCM 18.23
- 52 Week Low
- GOSS $0.50
- RDCM $8.85
- 52 Week High
- GOSS $1.55
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- GOSS 56.55
- RDCM 65.35
- Support Level
- GOSS $1.06
- RDCM $11.67
- Resistance Level
- GOSS $1.26
- RDCM $12.15
- Average True Range (ATR)
- GOSS 0.11
- RDCM 0.56
- MACD
- GOSS 0.04
- RDCM 0.20
- Stochastic Oscillator
- GOSS 70.09
- RDCM 96.92
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.